Pipeline Products

NOverdose is an app that connects opioid overdose victims with nearby volunteer naloxone carriers anonymously, plus, if desired will alert friends, neighbors, or peers that carry naloxone and also will text 911. Our goal is to support the substance abuse community (peer to peer) and those at elevated risk of opioid overdose with prescribed opioids.

We have completed IRB-approved functionality tests at the Albany College of Pharmacy and Health Sciences and also Western New England University College of Pharmacy. Release of this product is pending based on completing a staged release and funding.

Check out our promo video!

Phenotel

Currently under development is our comprehensive pharmacogenetic application with focus on guidance for implementing, justifying, and ordering phenotype and genotype analysis for patients. Our intent is to provide therapeutic decision algorithms for unique and individualized therapy selection by pharmacotherapeutic drug category and disease state. Check back on this for more details soon!

TAPERtel

This is still in concept phase.  Considering the opioid landscape and that fact that many clinicians are feeling forced to taper opioids due to various state and federal guidelines, coupled with insurance payer mandates, a software application to help guide clinicians will be a welcomed asset. This will help clinicins to determine if an opioid taper is a reasonable option, and if so, will help guide an adequate taper while preserving patient safety.

ORAtel

This new product is an offshoot of Naloxotel.  In essence, it provides a predicted percent risk of opioid induced respiratory depression and will have a new feature which predicts risk of opioid abuse and misuse. Planned release is fall 2018.

Supportive Literature

  1. Fudin J, Atkinson TJ. Personalized Oxycodone Dosing: Using Pharmacogenetic Testing and Clinical Pharmacokinetics to Reduce Toxicity Risk and Increase Effectiveness. Editorial. Pain Medicine. May 2014. 15(5):723–725.
  2. Janicki PK. Pharmacogenomics of Pain Management. In Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches. Deer TR. et al. (eds.), American Academy of Pain Medicine 2013:23-33.
  3. Owusu-Obeng A, Weitzel KW,4 Hatton RC, Staley BJ, Ashton J, Cooper-Dehoff RM, Johnson JA. Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics. Pharmacotherapy. 2014. 34(10): 1102-12.
  4. Flockhart DA, Lu WJ. Pharmacogenetics: Personalizing Pain Medicine. Supplement in Practical Pain Management. 2014 September; 14(8):49-57.
  5. Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine. 2012:5 73–87.
  6. Linares O, Michel T, Fudin J, Boston RC, Daly AM. Letter to the editor in Pain Physician. Integrating Clinical Pharmacokinetics, Pharmacogenetics, and Quantitative Cytochrome P450 Polymorphic Gene Drug-Drug Interactions (DDIs). Pain Physician. 2015; In press.